Regen BioPharma, Inc. Reports Success of its NR2F6 Small Molecule Screening Program for Treating Autoimmune Diseases

Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), has identified a series of small molecule drugs that inhibit NR2F6. Regen’s screening process…